A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
SummaryFollowing laparoscopic diagnosis and staging (American Fertility Society) of endometriosis, 269 patients, recruited from 10 hospitals, were allocated at random to groups receiving either gestrinone (2—5 mg) twice weekly (n = 132) or danazol (200 mg) twice daily (n = 137) for 6 months. Symptoms of endometriosis and clinical assessments were recorded at recruitment, monthly during treatment and at 1, 2, 3, 6, 9 and 12 months after treatment. Elimination or reduction of visible endometriosis was seen at laparoscopy after treatment in 42 (77 per cent) of gestrinone and 39 (82 per cent) of danazol treated patients. Lower abdominal pain, dysmenorrhoea and dyspareunia were reduced with both treatments. Side effects were reported by 91 per cent of gestrinone and 89 per cent of danazol patients, but only 19 per cent of the gestrinone group and 21 per cent in the danazol group withdrew. In 76 per cent of those withdrawing the reason was treatment related.Recurrence of the symptoms was low in 173 patients completing 12 months follow up. Pregnancy rates after treatment were 31 per cent in gestrinone and 18 per cent in danazol treated patients.In conclusion, gestrinone is as safe and effective as danazol in treating and in preventing recurrence of the symptoms of endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evers, J. L. H. (1987) · Fertility and Sterility · doi:10.1016/s0015-0282(16)59062-1 · Cited by 118
Cited by
Reevaluating response and failure of medical treatment of endometriosis: a systematic review
Becker, C. M., Gattrell, W. T., Gude, K., & Singh, S. S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.004 · Cited by 302
“Approximately one-third of patients treated with danazol (median 32%, range 8%–75%, six treatment arms) (9, 12, 18, 20, 22, 69) or GnRH agonists (median 34%, range 22%–67%, seven treatment arms) (18, 20, 22, 54, 69) had recurrence of pain symptoms after median follow-up periods of 12 months and 9 months, respectively.”
BackgroundInfluentialProgestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Ovulation suppression for endometriosis for women with subfertility
Hughes, E., Brown, J., Collins, J. J., Farquhar, C., Fedorkow, D. M., & Vanderkerchove, P. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000155.pub2 · Cited by 121
Mifepristone 2.5, 5, 10mg versus placebo in the treatment of endometriosis
Carbonell, J. L., Riverón, A. M., Leonard, Y., González, J., Heredia, B., & Sánchez, C. (2016) · Journal of Reproductive Health and Medicine · doi:10.1016/j.jrhm.2015.09.001 · Cited by 25
Metadata
- Authors
- Bromham, D. R., Booker, M. W., Rose, G. L., Wardle, P. G., & Newton, J. R.
- Venue
- Journal of Obstetrics and Gynaecology
- Publisher
- Informa UK Limited
- Published
- 1995-01
- Volume
- 15
- Issue
- 3
- Pages
- 188-194
- ISSN
- 0144-3615 (ISSN-L)
- 1364-6893
- OpenAlex
- W2030580713
- Cited by
- 26
- References
- 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis. https://app.cochat.ai/papers/10.3109/01443619509015498
- The paper
- Bromham, D. R., Booker, M. W., Rose, G. L., Wardle, P. G., & Newton, J. R. (1995). A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis. Journal of Obstetrics and Gynaecology. https://doi.org/10.3109/01443619509015498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.